BDSXHealthcare · Diagnostics & ResearchThe 7 Wall Street analysts covering Biodesix, Inc. hold a median 12-month price target of $34 — +31.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 87 of 100 as at 22 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Biodesix, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Revisions (96): Analysts have, on balance, been raising their forecasts.
Value (18): The shares cost a lot relative to the profits and assets behind them.
Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.
The bullish and bearish analyst opinions on BDSX, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +31.9% from it.
Of the 20 most recent actions, 3 moved their price target up and 0 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 10 Aug 2026 | Canaccord Genuity | Maintains | Buy | $27 → $35 |
| 6 Aug 2026 | HC Wainwright & Co. | Maintains | Buy | $26 → $27 |
| 25 June 2026 | Roth Capital | Initiates | Buy | — |
| 25 June 2026 | Roth Capital | Initiates | Buy | $32 |
| 18 June 2026 | Canaccord Genuity | Maintains | Buy | — |
| 18 June 2026 | Canaccord Genuity | Maintains | Buy | $22 → $27 |
| 15 June 2026 | HC Wainwright & Co. | Initiates | Buy | — |
| 5 May 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 Feb 2026 | William Blair | Upgrade | Outperform | — |
| 17 Feb 2026 | Canaccord Genuity | Maintains | Buy | — |
| 19 Sept 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 May 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 14 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 14 May 2025 | Craig-Hallum | Maintains | Buy | — |
| 14 May 2025 | Lake Street | Maintains | Buy | — |
| 14 May 2025 | William Blair | Downgrade | Market Perform | — |
| 29 Apr 2025 | Canaccord Genuity | Maintains | Buy | — |
| 16 Sept 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 26 July 2024 | Craig-Hallum | Initiates | Buy | — |
| 13 May 2024 | TD Cowen | Initiates | Buy | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Computed off the Friday close and sent before the US open.
Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. BDSX appears on the weeks it earns a place.
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 24 Aug 2026, Biodesix, Inc. returned +180.2% against +19.6% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 90% of US stocks
Cheaper than 45% of US stocks
Cheaper than 4% of US stocks
Cheaper than 89% of US stocks
Higher than 80% of US stocks
Higher than 69% of US stocks
Higher than 92% of US stocks
Higher than 22% of US stocks
Higher than 14% of US stocks
Higher than 3% of US stocks
Higher than 23% of US stocks
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Biodesix, Inc. has a market value of $281.0M and an enterprise value of $322.8M.
Revenue in the twelve months to 30 June 2026: $102.9M. The latest quarter grew 34.2% year on year.
Net income over the same four quarters: −$27.8M, a −27.0% net margin.
Diluted earnings per share, trailing twelve months: $−3.17.
Free cash flow in the twelve months to 30 June 2026: −$20.4M.
Trailing P/E: −5.7×; forward P/E: −121.0× — the forward figure prices analyst consensus estimates, not reported earnings.
Biodesix, Inc. employs 334 people — $308K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Biodesix, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Zacks Investment Research published an article comparing Precipio and Biodesix, two companies taking different approaches to cancer diagnostics, to assess which stock currently looks more compelling.
Why it matters — BDSX watchers would care because the piece offers a direct comparative analysis of Biodesix against a peer in the cancer diagnostics space.
At the Canaccord conference, Biodesix (NASDAQ: BDSX) identified commercial expansion, broader primary care outreach, and recently published clinical data supporting its Nodify CDT test in smaller lung nodules as key drivers of its growth strategy, while reaffirming its revenue outlook.
Why it matters — A BDSX watcher would care because the company reaffirmed its revenue outlook and highlighted the Nodify CDT test's expanding role as a growth driver.
Biodesix (BDSX) has reached a 52-week high in its stock price. The article examines the company's fundamentals to assess whether further gains may be possible following this high point.
Why it matters — BDSX watchers would care because the stock hitting a 52-week high prompts an evaluation of the company's underlying fundamentals to gauge the sustainability of its recent performance.
A Zacks Investment Research article notes that the consensus price target for Biodesix (BDSX) implies roughly 31.9% upside potential. The piece also observes that while this metric is regarded as hardly effective, an upward trend in earnings estimate revisions could signal near-term upside for the stock.
Why it matters — This item highlights what Wall Street analysts currently project for Biodesix's valuation and points to improving earnings estimate revisions that BDSX watchers may find relevant.
Seeking Alpha published the Q2 2026 earnings call transcript for Biodesix, Inc. (BDSX). The item consists only of the headline and attribution, with no details on the company's results or commentary.
Why it matters — A BDSX watcher would care because the transcript is the primary record of management's Q2 2026 discussion, though this excerpt contains no reporting on the content.
The 7 Wall Street analysts covering Biodesix, Inc. have a median 12-month price target of $34, with estimates ranging from $27 to $40. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 7 analysts covering Biodesix, Inc., 7 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Biodesix, Inc. 87 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.
As at 22 Aug 2026, Biodesix, Inc. ranks 87 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (96 of 100).
No one can know that. What the data says: the median 12-month target from 7 analysts implies +31.9% from the last close, and Ticker Nerd's factor model ranks Biodesix, Inc. 87 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Biodesix, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for BDSX are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $27 to $40 over the next 12 months.
Biodesix, Inc. returned +180.2% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.
Biodesix Inc. is a leading diagnostic solutions company specializing in blood-based molecular diagnostics for lung disease and oncology.
The most recent item we track (Zacks Investment Research, 24 Aug 2026): "PRPO vs. BDSX: Which Cancer Diagnostics Stock Is the Better Buy Now?". Zacks Investment Research published an article comparing Precipio and Biodesix, two companies taking different approaches to cancer diagnostics, to assess which stock currently looks more compelling.
Biodesix Inc. is a leading diagnostic solutions company specializing in blood-based molecular diagnostics for lung disease and oncology. It provides advanced diagnostic testing services, including the Nodify Lung suite such as Nodify CDT® and Nodify XL2® for lung nodule risk assessment, and IQLung for cancer treatment guidance. Additional tests encompass VeriStrat® for proteomic stratification in non-small cell lung cancer, GeneStrat® for genomic mutation detection via next-generation sequencing, and other offerings supporting precision oncology. Biodesix Inc. operates CLIA-certified, CAP-accredited laboratories employing technologies like proteomics, genomics, droplet digital PCR, and mass spectrometry to enable noninvasive, personalized clinical decisions for pulmonologists and oncologists. Complementing its diagnostics, the company delivers development services to biopharmaceutical and life sciences partners, including diagnostic research, clinical trial testing, companion diagnostics development, and commercialization support. These services facilitate innovation in precision medicine across lung cancer, breast cancer, and related areas. Headquartered in Louisville, Colorado, Biodesix Inc. plays a vital role in enhancing patient outcomes through timely, evidence-based diagnostic insights in the healthcare sector.
CEO Mr. Scott Hutton · 334 employees · United States · https://www.biodesix.com
